PERHAPS A GIFT VOUCHER FOR MUM?: MOTHER'S DAY

Close Notification

Your cart does not contain any items

$416.95

Paperback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
29 September 2021
Autonomic dysfunction is one of the most prevalent non-motor symptoms that occurs in Parkinson’s disease. Autonomic Dysfunction in Parkinson's Disease provides up to date information on this important topic, which affects quality of life of these patients. This include a large number of domains: orthostatic hypotension, excessive sweating, dry eyes, constipation, weight loss, increased sensitivity to heat and cold, sexual dysfunction.

Edited by:   , , , , ,
Imprint:   Academic Press Inc
Country of Publication:   United Kingdom
Dimensions:   Height: 229mm,  Width: 152mm, 
Weight:   450g
ISBN:   9780323851220
ISBN 10:   0323851223
Series:   International Review of Movement Disorders
Pages:   314
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active

Cristian Falup-Pecurariu is Head of the Department of Neurology, County Clinic Hospital from Brasov, and is Full Professor of Neurology at the Transilvania University from Brasov, Romania. He received his medical degree from the University of Medicine and Pharmacy “Iuliu Hatieganu” from Cluj-Napoca. He hold a 1 year fellowship of the European Neurological Society in movement disorders at Hospital Clinic, University of Barcelona, Spain. During his career Cristian Falup-Pecurariu was President of the European Association of Young Neurologists and Trainees (EAYNT), EAYNT Liasion Officer with World Federation of Neurological Society, co-representative of Europe on the International Working Group for Young Neurologists and Trainees (World Federation of Neurology). He was also Secretary of the EFNS/MDS-ES Panel on Movement Disorders, member of the Educational Committee of MDS-ES, member of the MDS Leadership Task Force and European Academy of Neurology Scientific Panel Movement Disorders, member of the Teaching Course sub-Committee of the European Academy of Neurology (EAN), currently being member of the Program Committee of EAN. Falup-Pecurariu is former Chair of the Education Committee of the MDS-ES, former member of the Executive Committee of MDS-ES, former member of the International Executive Committee of MDS. He is the initiator and Course Director of the Movement Disorders Teaching Course held in Brasov (12th editions). His research focuses on motor and non-motor aspects of Parkinson’s diseases. Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

See Also